Evaluation of the Therapeutic Efficacy and Safety of Artificial Intelligence-based Decision-making Technology in the Integrated Management of Diabetes Mellitus: a Longitudinal, Open-labeled, Randomized Controlled Trial
Trial ID: NCT06957093
Status: RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2025-06-15
Completion date: 2026-12
Sponsor: The First Hospital of Jilin University
Conditions: Diabetes Mellitus Type 2 (T2DM); Artificial Intelligence (AI)
Interventions: artificial intelligence; Routine diagnosis and treatment group for diabetes
Locations: The First Hospital of Jilin University
Countries: China
Enrollment: 400
Age range: 18 Years - 75 Years
Sex: ALL

Summary:
Purpose: To evaluate the efficacy of artificial intelligence (AI)-based decision-making technology in managing glycated hemoglobin (HbA1c) and blood glucose levels compared to the control group.

Methods: For the AI Intervention group, the patients will be trained to independently use the diabetes telemedicine platform application. Each patient will be equipped with a glucometer and exercise bracelet, and the data will be automatically transmitted to the medical server via Bluetooth. The healthcare platform will analyze the uploaded data and provide feedback suggestions on medication, diet, and exercise automatically. The platform will also monitor the medical and lifestyle data of the patients every two weeks, offer feedback based on the analyses, and remind the patient to adhere to the self-management protocol based on the platform. The platform is a digitally integrated healthcare platform that patients can use independently without the need for monitoring and assistance by healthcare professionals. The glucometer and pedometer bracelet will automatically connect to the platform through Bluetooth. The patient lab sheet identification and structured conversion system, AI for food picture identification and calorie calculation systems, and the AI decision-making system are on the cloud server. Patients upload image information, such as lab sheets and meal pictures, through the patient's diabetes mobile health system, and the cloud platform intelligently analyzes the patient's disease, medication, and daily life status to develop personalized solutions according to individual control goals. Free outpatient visits will be provided to both the intervention and control groups every twelve weeks. For the conventional treatment group, patients will receive a free blood glucometer and will have regular outpatient appointments. There is no limit to the number of outpatient visits; however, they are required to regularly monitor and record their blood glucose, diet, and exercise data to ensure that the medical team objectively conduct their diagnosis and treatment activities. The medical team will provide free outpatient visits every 12 weeks, along with advice on medication, diet, and exercise based on the individual's blood glucose level.

Expected results: A significant difference in HbA1c change from baseline to 48 weeks and improved FPG and 2-hour postprandial blood glucose levels in the AI intervention group were observed.

Eligibility criteria:
Inclusion Criteria：

* Age: ≥18 years，≤75 years;
* Diagnosed with type 2 diabetes for ≥1 year;
* 7.0% ≤HbA1c ≤11%;
* Body mass index ≥18.5 kg/m2;
* Proficient ability to use smart phones;
* Agreed to utilize a digital integrated healthcare platform for diabetes care and research;
* Informed consents are obtained from the participants.

Exclusion Criteria:

* Presence of other types of diabetes, such as type 1 diabetes and gestational diabetes;
* Severe diabetic complications;
* Medical history of chronic liver diseases, including hemochromatosis, hepatocellular carcinoma, autoimmune liver disease, cirrhosis, viral hepatitis (including hepatitis A, B, and C), or hepatolenticular degeneration;
* Kidney injury (serum creatinine ≥1.5 times the upper limit of the reference) ; Serum ALT and AST levels elevated \>2-fold;
* Medical history of mental disorders, such asschizophrenia, depression, or bipolar affective disorder;
* Excessive alcohol intake or drug abuse in the past 3 months;
* Use of medications affecting glucose metabolism, such as corticosteroids or ·consumption of immunosuppressive and anti-obesity medications in the past 3 months;
* Pregnancy, planning for pregnancy, or lactation; or any other conditions unsuitable for trial participation;
* Participatingor plan to participate in other clinical trials; and other cases that are inappropriate to participate.

Outcomes:
HbA1c; Fasting Blood Glucose (FBG); 2-hour Postprandial Blood Glucose (2hPPG); Hypoglycemic events